ASX Release **25 November 2026**
ASX Code: MEM

Annual General Meeting – Withdrawal of Resolution

Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") advises that it has withdrawn "Resolution 7 – Approval of 10% Placement Capacity" which was to be considered at the Company's Annual General Meeting (AGM) scheduled today at 2:00pm (AEDT) on Wednesday, 25 November 2026.

Following feedback received from shareholders and given that Memphasys currently has no intention to utilise the additional placement capacity provided under ASX Listing Rule 7.1A, the Board has determined it is appropriate to withdraw this resolution.

The withdrawal of Resolution 7 will not affect the validity of proxy votes already submitted in respect of the other resolutions to be considered at the AGM. All other resolutions remain unchanged and will be put to shareholders at the meeting.

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby
Chapter One Advisors
Tel: +61 439 980 359
E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian reproductive biotechnology company commercialising the Felix™ System, a patented sperm preparation technology using electrophoresis and size-exclusion membranes to isolate sperm for assisted reproduction. The system comprises a benchtop console and single-use cartridges.

Website: www.memphasys.com